Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance

Nature Communications

Volumn 7, Issue , 2016, Pages

  Kabe, Yasuaki ^a   Nakane, Takanori ^b   Koike, Ikko ^a   Yamamoto, Tatsuya ^c   Sugiura, Yuki ^a   Harada, Erisa ^c   Sugase, Kenji ^c   Shimamura, Tatsuro ^b   Ohmura, Mitsuyo ^a   Muraoka, Kazumi ^a   Yamamoto, Ayumi ^d   Uchida, Takeshi ^d   Iwata, So ^b,e   Yamaguchi, Yuki ^f   Krayukhina, Elena ^g   Noda, Masanori ^g   Handa, Hiroshi ^h   Ishimori, Koichiro ^d   Uchiyama, Susumu ^g,i   Kobayashi, Takuya ^b,e   Suematsu, Makoto ^a   more..

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c SUNTORY INSTITUTE FOR BIOORGANIC RESEARCH   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^f TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^g OSAKA UNIVERSITY   (Japan)

^h TOKYO MEDICAL UNIVERSITY   (Japan)

ⁱ OKAZAKI INSTITUTE FOR INTEGRATIVE BIOSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; CYTOCHROME P450; DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; HEME; SIGMA 2 OPIATE RECEPTOR; MEMBRANE PROTEIN; PGRMC1 PROTEIN, HUMAN; PROGESTERONE RECEPTOR; PROTEIN BINDING; SIGMA OPIATE RECEPTOR; SIGMA-2 RECEPTOR; SOLUTION AND SOLUBILITY;

CANCER; CARBON MONOXIDE; CELLS AND CELL COMPONENTS; CYTOCHROME; DRUG; MEMBRANE; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIMERIZATION; DRUG RESISTANCE; GEL FILTRATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROGEN BOND; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN SECONDARY STRUCTURE; X RAY CRYSTALLOGRAPHY; BIOLOGICAL MODEL; DRUG EFFECTS; METABOLISM; NEOPLASM; PATHOLOGY; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION; SOLUTION AND SOLUBILITY;

EUKARYOTA;

CARBON MONOXIDE; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, NEOPLASM; HEME; HUMANS; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PROGESTERONE; RECEPTORS, SIGMA; SIGNAL TRANSDUCTION; SOLUTIONS;

EID: 84961627486     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11030     Document Type: Article

References (66)

1. Kowdley, K. V. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 127, S79-S86 (2004).
2. Jakszyn, P. et al. Meat and heme iron intake and esophageal adenocarcinoma in the European prospective investigation into cancer and nutrition study. Int. J. Cancer. 133, 2744-2750 (2013).
3. Bastide, N. M., Pierre, F. H. & Corpet, D. E. Heme iron from meat and risk of colorectal cancer: a meta-analysis and a review of the mechanisms involved. Cancer Prev. Res. (Phila.) 4, 177-184 (2011).
4. Shen, J. et al. Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability and function. Cell Rep. 7, 180-193 (2014).
5. Hooda, J. et al. Enhanced heme function and mitochondrial respiration promote the progression of lung cancer cells. PLoS ONE 8, e63402 (2013).
6. Wegiel, B. et al. Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. Cancer Res. 73, 7009-7021 (2013).
7. Yamamoto, T. et al. Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway. Nat. Commun. 5, 3480 (2014).
8. Sakamoto, S., Kabe, Y., Hatakeyama, M., Yamaguchi, Y. & Handa, H. Development and application of high-performance affinity beads: toward chemical biology and drug discovery. Chem. Rec. 9, 66-85 (2009).
9. 5-like ligand-binding domain. Genome. Biol. 3, RESEARCH0068 (2002).
10. Neubauer, H. et al. Possible role of PGRMC1 in breast cancer development. Climacteric 16, 509-513 (2013).
11. Craven, R. J. PGRMC1: a new biomarker for the estrogen receptor in breast cancer. Breast Cancer Res. 10, 113 (2008).
12. Peluso, J. J., Liu, X., Saunders, M. M., Claffey, K. P. & Phoenix, K. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J. Clin. Endocrinol. Metab. 93, 1592-1599 (2008).
13. Friel, A. M. et al. Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors. Cancer Lett. 356, 434-442 (2015).
14. Nie, A. Y. et al. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol. Carcinog. 45, 914-933 (2006).
15. Mir, S. U., Ahmed, I. S., Arnold, S. & Craven, R. J. Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients. Int. J. Cancer 131, E1-E9 (2012).
16. Hornick, J. R., Spitzer, D., Goedegebuure, P., Mach, R. H. & Hawkins, W. G. Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. Surgery 152, S152-S156 (2012).
17. Crudden, G., Loesel, R. & Craven, R. J. Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors. Tumour Biol. 26, 142-146 (2005).
18. Ahmed, I. S., Rohe, H. J., Twist, K. E. & Craven, R. J. Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. J. Biol. Chem. 285, 24775-24782 (2010).
19. Hughes, A. L. et al. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab. 5, 143-149 (2007).
20. Ahmed, I. S., Rohe, H. J., Twist, K. E., Mattingly, M. N. & Craven, R. J. Progesterone receptor membrane component 1 (Pgrmc1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule. J. Pharmacol. Exp. Ther. 333, 564-573 (2010).
21. Ahmed, I. S., Chamberlain, C. & Craven, R. J. S2R(Pgrmc1): the cytochromerelated sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling. Expert Opin. Drug. Metab. Toxicol. 8, 361-370 (2012).
22. Kaluka, D., Batabyal, D., Chiang, B. Y., Poulos, T. L. & Yeh, S. R. Spectroscopic and mutagenesis studies of human PGRMC1. Biochemistry 54, 1638-1647 (2015).
23. Min, L. et al. Molecular identification of adrenal inner zone antigen as a hemebinding protein. FEBS J. 272, 5832-5843 (2005).
24. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774-797 (2007).
25. Shen, Y., Delaglio, F., Cornilescu, G. & Bax, A. TALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shifts. J. Biomol. NMR. 44, 213-223 (2009).
26. Ohto, U. et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature 520, 702-705 (2015).
27. Nogi, T. et al. Structural basis for semaphorin signalling through the plexin receptor. Nature 467, 1123-1127 (2010).
28. Ishikawa, H. et al. Involvement of heme regulatory motif in heme-mediated ubiquitination and degradation of IRP2. Mol. Cell. 19, 171-181 (2005).
29. Liu, Y. et al. Replacement of the proximal histidine iron ligand by a cysteine or tyrosine converts heme oxygenase to an oxidase. Biochemistry 38, 3733-3743 (1999).
30. Kubo, A. et al. Semi-quantitative analyses of metabolic systems of human colon cancer metastatic xenografts in livers of superimmunodeficient NOG mice. Anal. Bioanal. Chem. 400, 1895-1904 (2011).
31. Bao, Y. et al. Energy management by enhanced glycolysis in G1-phase in human colon cancer cells in vitro and in vivo. Mol. Cancer Res. 11, 973-985 (2013).
32. Quintieri, L. et al. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A. Cancer Res. 60, 3232-3238 (2000).
33. McFadyen, M. C. et al. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem. Pharmacol. 62, 207-212 (2001).
34. Szczesna-Skorupa, E. & Kemper, B. Progesterone receptor membrane component 1 inhibits the activity of drug-metabolizing cytochromes P450 and binds to cytochrome P450 reductase. Mol. Pharmacol. 79, 340-350 (2011).
35. Higashimoto, Y. et al. Involvement of NADPH in the interaction between heme oxygenase-1 and cytochrome P450 reductase. J. Biol. Chem. 280, 729-737 (2005).
36. Wakasugi, K., Nakano, T. & Morishima, I. Oxidized human neuroglobin acts as a heterotrimeric Galpha protein guanine nucleotide dissociation inhibitor. J. Biol. Chem. 278, 36505-36512 (2003).
37. Lucas, A. T. et al. Ligand binding reveals a role for heme in translationally controlled tumor protein dimerization. PLoS ONE 9, e112823 (2014).
38. Watanabe, M. et al. Structural basis for multimeric heme complexation through a specific protein-heme interaction: the case of the third neat domain of IsdH from Staphylococcus aureus. J. Biol. Chem. 283, 28649-28659 (2008).
39. Cahill, M. A. Progesterone receptor membrane component 1: an integrative review. J. Steroid Biochem. Mol. Biol. 105, 16-36 (2007).
40. Peluso, J. J., Griffin, D., Liu, X. & Horne, M. Progesterone receptor membrane component-1 (PGRMC1) and PGRMC-2 interact to suppress entry into the cell cycle in spontaneously immortalized rat granulosa cells. Biol. Reprod. 91, 104 (2014).
41. Craven, R. J., Mallory, J. C. & Hand, R. A. Regulation of iron homeostasis mediated by the heme-binding protein Dap1 (damage resistance protein 1) via the P450 protein Erg11/Cyp51. J. Biol. Chem. 282, 36543-36551 (2007).
42. Oda, S., Nakajima, M., Toyoda, Y., Fukami, T. & Yokoi, T. Progesterone receptor membrane component 1 modulates human cytochrome P450 activities in an isoform-dependent manner. Drug Metab. Dispos. 39, 2057-2065 (2011).
43. Lin, S. T. et al. PGRMC1 contributes to doxorubicin-induced chemoresistance in MES-SA uterine sarcoma. Cell. Mol. Life Sci. 72, 2395-2409 (2015).
44. Wendler, A., Keller, D., Albrecht, C., Peluso, J. J. & Wehling, M. Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cells. Oncol. Rep. 25, 273-279 (2011).
45. Liu, N., Zhou, C., Zhao, J. & Chen, Y. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Cancer Invest. 30, 577-582 (2012).
46. 2S gas biology. Antioxid. Redox. Signal. 13, 157-192 (2010).
47. Kyokane, T. et al. Carbon monoxide from heme catabolism protects against hepatobiliary dysfunction in endotoxin-treated rat liver. Gastroenterology 120, 1227-1240 (2001).
48. Suematsu, M. & Ishimura, Y. The heme oxygenase-carbon monoxide system: a regulator of hepatobiliary function. Hepatology 31, 3-6 (2000).
49. Chen, C. & Paw, B. H. Cellular and mitochondrial iron homeostasis in vertebrates. Biochim. Biophys. Acta. 1823, 1459-1467 (2012).
50. Frezza, C. et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477, 225-228 (2011).
51. Lee, W. Y. et al. The induction of heme oxygenase-1 suppresses heat shock protein 90 and the proliferation of human breast cancer cells through its byproduct carbon monoxide. Toxicol. Appl. Pharmacol. 274, 55-62 (2014).
52. Xu, J. et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat. Commun. 2, 380 (2011).
53. Izzo, N. J. et al. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS ONE 9, e111899 (2014).
54. Qin, Y. et al. Progesterone attenuates Abeta25-35-induced neuronal toxicity via JNK inactivation and progesterone receptor membrane component 1-dependent inhibition of mitochondrial apoptotic pathway. J. Steroid Biochem. Mol. Biol. 154, 302-311 (2015).
55. Sahlholm, K., Liao, F., Holtzman, D. M., Xu, J. & Mach, R. H. Sigma-2 receptor binding is decreased in female, but not male, APP/PS1 mice. Biochem. Biophys. Res. Commun. 460, 439-445 (2015).
56. Kabsch, W. XDS. Acta. Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
57. Terwilliger, T. C. et al. Decision-making in structure solution using Bayesian estimates of map quality: the PHENIX AutoSol wizard. Acta. Crystallogr. D Biol. Crystallogr. 65, 582-601 (2009).
58. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta. Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
59. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta. Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
60. Schuck, P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys. J. 78, 1606-1619 (2000).
61. Brookes, E., Demeler, B., Rosano, C. & Rocco, M. The implementation of SOMO (SOlution MOdeller) in the UltraScan analytical ultracentrifugation data analysis suite: enhanced capabilities allow the reliable hydrodynamic modeling of virtually any kind of biomacromolecule. Eur. Biophys. J. 39, 423-435 (2010).
62. Wu, D. H., Chen, A. D. & Johnson, C. S. An improved diffusion-ordered spectroscopy experiment incorporating bipolar-gradient pulses. J. Magn. Reson. A. 115, 260-264 (1995).
63. Esturau, N. et al. The use of sample rotation for minimizing convection effects in self-diffusion NMR measurements. J. Magn. Reson. 153, 48-55 (2001).
64. Suematsu, M. et al. Carbon monoxide: an endogenous modulator of sinusoidal tone in the perfused rat liver. J. Clin. Invest. 96, 2431-2437 (1995).
65. Goda, N. et al. Distribution of heme oxygenase isoforms in rat liver. Topographic basis for carbon monoxide-mediated microvascular relaxation. J. Clin. Invest. 101, 604-612 (1998).
66. Nagai, T. et al. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat. Biotechnol. 20, 87-90 (2002).